期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌化疗药物的研究进展及临床应用评价 被引量：8

Research and Development and Clinical Evaluation of the Drugs Used for Chemotherapy of Breast Cancer
暂未订购
导出
摘要 目的:介绍乳腺癌化疗药物的研究进展,评价其在乳腺癌治疗中的临床应用概况。方法:查阅近期国内外相关文献进行分析与评价。结果与结论:20世纪90年代以后,乳腺癌化疗药物的研究进展迅速,乳腺癌化疗药物的联合应用疗效明显提高。 OBJECTIVE： To summarize the aspect of clinical usage and progress of the drugs used for chemotherapy of breast cancer and evaluate their clinical curative effect and safety. METHODS： To collect medical leteratures in recent years at home and abroad for an analysis. RESULTS ＆ CONCLUSION ： Advance in clinical research on the chemotherapeutic drugs for breast cancer has been swift since the nineties of the 20th century. Combined use of chemotherapeutic drugs can obviously improve clinical curative effect.
作者 刘贤铭
机构地区 江苏省肿瘤医院
出处 《中国医院用药评价与分析》 2005年第4期214-216,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 乳腺癌 化疗药物 临床评价 breast cancer chemotherapeutic drugs clinical evaluation
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献18

  • 1杨磊,樊红.紫杉类抗肿瘤药物的临床应用进展[J].中国医院用药评价与分析,2004,4(1):58-60. 被引量：23
  • 2苏卫,孙素华.以紫杉醇为主的联合化疗方案治疗转移性乳腺癌[J].临床肿瘤学杂志,2003,8(3):186-187. 被引量：11
  • 3Henderson C,Berry DA,Demetri GD,et al.Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node - positive primary breast cancer [J].J Clin Oncol,2003,21 (6):976.
  • 4Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety of humanized anti - HER2monoclonal antibody in women who have HER2 expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease[J].J Clin Oncol,1999,17(9):2 639.
  • 5Pegram MD,Hsu S,Lewis G,et al.Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer [J].Oncogene,1999,18(13) :2 241.
  • 6Satmon DJ,Leylang Jones B,Shak S,et al.Use of chemotherapy plus a molmclonal antibody against HER - 2 for metastatic breast cancer that overexpresses HER - 2 [J].N Engl J Med ,2001,344 ( 11 ) :783.
  • 7Seidman AD,Fornier MN,Esteva FJ,et al.Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplicationl [J].J Clin Oncol,2001,19(10) :2 587.
  • 8Esteva FJ,Valero V,Booser D,et al.Phase Ⅱ study of weekly docetaxel and trastuzumab for patients with HER2 -overexpressing metastatic breast cancer [J] .J Clin Oncol,2002,20(7):1 800.
  • 9Burris HA.Docetaxel(taxotere) plus trastuzumab (herceptin) in breast cancer[J] .Semin Oncol,2001,28(Supp3.1 ) :38.
  • 10Burstein HJ,Kuter L,Campos SM,et al.Clinical activity of trastuzumab and vinorelbine in women with HER2 -overexpressing metastatic breast cancer[J].J Clin Oncol,2001,19(11) :2 722.

二级参考文献72

  • 1[1]Seidman AD,Tiersten A,Hudis C,et al. Phase Ⅱtrial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer[J].J Clin Oncol, 1995,13(10):2 575.
  • 2[5]Robert N,Leyland-Jones B, Asmar L,et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer[J].Breast Cancer Res Treat, 2002,76(supple): 37.
  • 3[6]Seidman AD, Fornier MN, Esteva FJ,et al.Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification[J].J Clin Oncol,2001,19(10):2 587.
  • 4[7]Henderson C,Berry DA,Demetri GD,et al. Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J]. J Clin Oncol,2003,21 (6): 976.
  • 5[8]Nabholtz JM,Pienkowski T,Mackey J,et al. Phase Ⅲ trial comparing TAC (docetaxel, doxorubicin,cyclophosphamide) with FAC (5-fluorouracil,doxorubicin,cyclophospha-mide) in the adjuvant treatment of node positive breast cancer(BC)patients: interim analysis of the BCIRG 001 study[A].ASCO, 2002,21:141 abstr.
  • 6[9]Pirker R, Krajnik G, Zochbauer S, et al. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC) [J].Ann Oncol, 1995,6(8):833.
  • 7[12]van Oosterom AT.Docetaxel(taxotere) and gemcitabine phase Ⅰ and early phase Ⅱ studies: results to date and an overview of ongoing studies[J].Semin Oncol, 1999,26(3 suppl 11): 8.
  • 8[15]Fossella FV,Belani CP.Phase Ⅲ study(TAX 326)of docetaxel-cisplatin and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin(VC) for the firstline treatment of advanced/metastatic non-smallcell lung cancer(NSCLC):analyses in elderly patients[A].ASCO,2003, 22:2 528 abstr.
  • 9[16]Ishikawa H,Nakanishi TT,Nawa A,et al.3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer[J].Int J Clin Oncol,2001,6(3): 128.
  • 10[17]Ghamande S,Lele S,Marchetti D,et al. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer[J].Int J Gynecol Cancer,2003,13(2): 142.

共引文献94

同被引文献76

引证文献8

二级引证文献20

中国医院用药评价与分析
2005年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部